NIH Exploratory/Developmental Research Project Grant (Parent R21 Basic Experimental Studies with Humans Required)

The NIH Exploratory/Developmental Research Project Grant (R21 Basic Experimental Studies with Humans Required) is administered by the National Institutes of Health within the U.S. Department of Health and Human Services. Multiple NIH Institutes and Centers participate, each contributing to a broad federal effort to advance biomedical, behavioral, and clinical research. The program is designed to stimulate innovative, high-risk, and exploratory studies involving human participants, particularly those that may lack extensive preliminary data but demonstrate strong potential to advance fundamental scientific understanding. The primary purpose of this funding opportunity is to support basic experimental studies involving human subjects that meet the NIH definition of both a clinical trial and basic research. These studies must prospectively assign participants to experimental conditions and evaluate biomedical or behavioral outcomes, with the goal of understanding fundamental mechanisms rather than developing or testing specific products or interventions. The program encourages novel ideas, unconventional approaches, and new methodologies that could significantly impact scientific knowledge and future health advancements. Funding under this program supports exploratory projects with a maximum project period of two years. The combined direct costs over this period may not exceed 275000 dollars, with no more than 200000 dollars requested in any single year. Funds may be used for research-related expenses consistent with NIH policies, including personnel, equipment, and study-related costs. There is no cost-sharing requirement. The program is not intended for long-term or well-established research areas, which are more appropriate for other NIH mechanisms such as the R01. Eligibility is broad and inclusive, encompassing higher education institutions, nonprofits, for-profit organizations, government entities at all levels, tribal governments, and foreign organizations. Individual principal investigators must have the expertise and institutional support necessary to conduct the proposed research. Applicants must complete required federal registrations, including SAM, Grants.gov, and eRA Commons, prior to submission. Multiple applications are allowed if each is scientifically distinct, but duplicate or overlapping submissions are not permitted. Applications must be submitted electronically through approved systems such as Grants.gov or NIH ASSIST. Required components include the SF424 forms, research plan, budget, human subjects documentation, and a data management and sharing plan. Applications must follow the NIH Application Guide and any program-specific instructions. Compliance is strictly enforced, and noncompliant applications may be rejected without review. All applications must include a clinical trial designation consistent with NIH definitions. The evaluation process involves peer review focusing on significance, innovation, rigor, feasibility, and investigator expertise. Reviewers assess the potential impact of the proposed research, the soundness of the approach, and the qualifications of the research team. Additional considerations include human subjects protections and data integrity. Applications that demonstrate strong potential for advancing knowledge are prioritized, even if they involve higher levels of uncertainty. This funding opportunity operates on recurring standard NIH submission cycles with multiple deadlines each year. The current closing date for applications is May 24, 2026, with additional cycles extending through January 2028. Applications are due by 5:00 PM local time of the applicant organization. Awards follow a structured timeline including peer review, advisory council review, and earliest start dates, typically several months after submission. Applicants are encouraged to apply early and ensure all materials are complete and compliant prior to submission.

Emphasize innovation and high impact; ensure strong scientific rationale; demonstrate feasibility despite exploratory nature; align with NIH definition of basic experimental studies with humans